Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
Johannes vom Berg, Melissa Vrohlings, Sergio Haller, et al.
The Journal of Experimental Medicine (2013) Vol. 210, Iss. 13, pp. 2803-2811
Open Access | Times Cited: 190

Showing 26-50 of 190 citing articles:

In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Linda Hammerich, Adam Binder, Joshua Brody
Molecular Oncology (2015) Vol. 9, Iss. 10, pp. 1966-1981
Open Access | Times Cited: 161
IL-12-and IL-23 in health and disease
Andrew L. Croxford, Paulina Kulig, Burkhard Becher
Cytokine & Growth Factor Reviews (2014) Vol. 25, Iss. 4, pp. 415-421
Closed Access | Times Cited: 145
Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet
Danielle M. Lussier, Eric C. Woolf, John L. Johnson, et al.
BMC Cancer (2016) Vol. 16, Iss. 1
Open Access | Times Cited: 139
The interplay of effector and regulatory T cells in cancer
Rahul Roychoudhuri, Robert Eil, Nicholas P. Restifo
Current Opinion in Immunology (2015) Vol. 33, pp. 101-111
Closed Access | Times Cited: 131
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme
Jiří Polívka, Jiří Polívka, L Holubec, et al.
Anticancer Research (2017) Vol. 37, Iss. 1
Open Access | Times Cited: 129
Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
Juming Yan, Mark J. Smyth, Michele W.L. Teng
Cold Spring Harbor Perspectives in Biology (2017) Vol. 10, Iss. 7, pp. a028530-a028530
Open Access | Times Cited: 125
Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression
Donal McHugh, Nicole Caduff, Mário Henrique M. Barros, et al.
Cell Host & Microbe (2017) Vol. 22, Iss. 1, pp. 61-73.e7
Closed Access | Times Cited: 119
T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints
Reza Mirzaei, Susobhan Sarkar, V. Wee Yong
Trends in Immunology (2016) Vol. 38, Iss. 2, pp. 104-115
Closed Access | Times Cited: 118
Neutrophils in Gliomas
Matteo Massara, Pasquale Persico, Ornella Bonavita, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 114
Glioblastoma Treatment Modalities besides Surgery
Hao Zhang, Ruizhe Wang, Yuanqiang Yu, et al.
Journal of Cancer (2019) Vol. 10, Iss. 20, pp. 4793-4806
Open Access | Times Cited: 114
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Serena Pellegatta, Lorella Valletta, Cristina Corbetta, et al.
Acta Neuropathologica Communications (2015) Vol. 3, Iss. 1
Open Access | Times Cited: 109
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Tobias Weiß, Emanuele Puca, Manuela Silginer, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 564
Closed Access | Times Cited: 101
Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models
Marcel Schneider, Laura Heeb, Michał Beffinger, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 611
Closed Access | Times Cited: 98
FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas
Jun Yan, Ling-Yuan Kong, Jiemiao Hu, et al.
JNCI Journal of the National Cancer Institute (2015) Vol. 107, Iss. 8
Open Access | Times Cited: 97
Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
Aria Sabbagh, Kévin Beccaria, Xiaoyang Ling, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 15, pp. 4325-4337
Open Access | Times Cited: 92
TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia
Jiawen Qian, Feifei Luo, Jiao Yang, et al.
Cancer Immunology Research (2018) Vol. 6, Iss. 10, pp. 1220-1233
Closed Access | Times Cited: 90
Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma
John Barrett, Hongliang Cai, John Miao, et al.
Cancer Gene Therapy (2018) Vol. 25, Iss. 5-6, pp. 106-116
Open Access | Times Cited: 87
In Situ Vaccination for the Treatment of Cancer
Linda Hammerich, Nina Bhardwaj, Holbrook E. Kohrt, et al.
Immunotherapy (2016) Vol. 8, Iss. 3, pp. 315-330
Closed Access | Times Cited: 86
Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization
Zhuang Li, Wenjuan Fu, Xiaohong Chen, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 59
Cytokine engineering for targeted cancer immunotherapy
Lucia Bonati, Li Tang
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 43-52
Open Access | Times Cited: 57
Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Hanna Meister, Thomas Look, Patrick Roth, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4747-4756
Open Access | Times Cited: 53
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Verena Turco, Kira Pfleiderer, Jessica Hunger, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 35
Recruiting T‐Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co‐Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage‐Membrane‐Camouflaged Nanovesicles
Xiaoxuan Xu, Zhi‐Qi Zhang, Jiawei Du, et al.
Advanced Materials (2023) Vol. 35, Iss. 25
Closed Access | Times Cited: 28
Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma
Thomas Look, Emanuele Puca, Marcel Bühler, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 697
Closed Access | Times Cited: 25
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
Ginette S. Santiago-Sánchez, Kellsye P. Fabian, James W. Hodge
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 15

Scroll to top